Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of treatments for cancer. It develops XYOTAX, a Phase III clinical trial chemotherapeutic agent, which links paclitaxel to a polyglutamate polymer, for the treatment of non-small cell lung cancer, ovarian, and other cancers; Pixantrone, an anthracycline derivative, for the treatment of non-Hodgkin’s lymphoma (NHL) and relapsed NHL; and CT-2106, which is in phase I/II studies for colorectal and ovarian cancers. The company also works on various drug targets in discovery research, which includes bisplatinum agents, HIF-1a/p300 inhibitors, and proteasome inhibitors with indirect inhibition...